

## 2016 Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

### Panel Member Conflict of Interest Disclosure

Member	Consulting fees / Honoraria	Clinical Trials	Ownership/ partnership/ principal	Intellectual property rights/ iduciary Role/other benefit
<b>Primary Panel</b>				
Sean Virani	Medtronic, Novartis, Otsuka, Pfizer, Roche, Servier	Byaer, Medtronic, Pfizer, Servier	None	None
Susan Dent	GlaxoSmithKline, Roche	GlaxoSmithKline, Roche	None	None
Christine Brezden-Masley	AMGEN, Bayer, Eli Lilly, Novartis, Roche, sanofi-aventis	Eli Lilly, Roche, Boston Biomedical	None	None
Brian Clarke	None	AMGEN	None	None
Margot Davis	None	Pfizer	None	None
Davinder Jassal	None	None	None	None
Christopher Johnson	Roche	None	None	None
Julie Lemieux	Roche	AMGEN, Roche	None	None
Ian Paterson	None	Servier	None	None
Igal Sebag	Lantheus (contrast in echocardiography)	None	None	None
Christine Simmons	AMGEN, AstraZeneca, Novartis, Roche	AstraZeneca, Novartis, Pfizer, Roche	None	None
Jeffery Sulpher	None	None	None	None
Kishore Thain	None	None	None	None
Dinesh Thavendiranathan	None	None	None	None
Jason Wentzall	None	None	Oncolytics Biotech (shareholder)	None
Nola Wurtele	None	None	None	None
<b>Secondary Panel</b>				
Marc André Côté	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Roche	None	None	None
Nowell Fine	None	None	None	None
Haissam Haddad	None	None	None	None
Brad Hayley	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer	None	None	None
Sean Hopkins	AMGEN, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Eli Lilly, Novartis, Johnson & Johnson, Pfizer, Roche, sanofi-aventis	None	None	None
Anil Abraham Joy	None	None	None	None
Daniel Rayson	AMGEN, Novartis, Roche, Pfizer	Novartis, Roche	None	None
Ellamae Stadnick	None	None	None	None
Lynn Straatman	None	Medtronic, Novartis, Otsuka	None	None